University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL

Natalie Galanina, Sonali M. Smith, Chuanhong Liao, Adam Petrich, Bernadette Libao, Ronald Gartenhaus, Jason R. Westin, Kenneth S. Cohen, James A. Knost, Walter M. Stadler, Austin Doyle, Theodore Karrison, Leo I. Gordon, Andrew M. Evens

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)264-267
Number of pages4
JournalBritish Journal of Haematology
Volume181
Issue number2
DOIs
StatePublished - Apr 2018

Keywords

  • MEK inhibition
  • novel therapies
  • relapsed/refractory DLBCL
  • selumetinib

ASJC Scopus subject areas

  • Hematology

Cite this

Galanina, N., Smith, S. M., Liao, C., Petrich, A., Libao, B., Gartenhaus, R., Westin, J. R., Cohen, K. S., Knost, J. A., Stadler, W. M., Doyle, A., Karrison, T., Gordon, L. I., & Evens, A. M. (2018). University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. British Journal of Haematology, 181(2), 264-267. https://doi.org/10.1111/bjh.14544